Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors

BACKGROUND: Avapritinib, a novel inhibitor of KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18‐mutant unresectable or metastatic gastrointestinal stromal tumors (U/M GISTs). We assessed the safety of avapritinib and provide evidence‐based guidance on management of...

Descripción completa

Detalles Bibliográficos
Autores principales: Joseph, Cissimol P., Abaricia, Sarah N., Angelis, Michelle A., Polson, Kathleen, Jones, Robin L., Kang, Yoon‐Koo, Riedel, Richard F., Schöffski, Patrick, Serrano, César, Trent, Jonathan, Tetzlaff, Eric D., Si, Tuan Dong, Zhou, Teresa, Doyle, Ashley, Bauer, Sebastian, Roche, Maria, Havnaer, Tracy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Gastrointestinal Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018323/
https://www.ncbi.nlm.nih.gov/pubmed/33301227
http://dx.doi.org/10.1002/onco.13632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018323/
https://www.ncbi.nlm.nih.gov/pubmed/33301227
http://dx.doi.org/10.1002/onco.13632

Ejemplares similares